Survey
Quarterly Survey: Low Risk MDS and Treatments including Rytelo (imetelstat) and Reblozyl (luspatercept) April 2025
Ticker(s): GERN, XLRN, MRK, ELRN, BMYThe survey includes 20 Hematologists.
How many patients with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell transfusions do you treat?
How familiar are you with the updated label for Reblozyl (luspatercept) and the recent approval for Rytelo (imetelstat)?
- Very familiar:
- Somewhat familiar:
- Not at all familiar:
How would you best describe your practice?
- Private
- Academic
- Community
Of the LR-MDS patients under your care, what percent fall into each of the following categories?
- Currently on 1L systemic therapy:
- Currently on 2L systemic therapy:
- Currently on 3L systemic therapy:
How many LR-MDS patients requiring red blood cell transfusions are you currently treating with the following:
- Epoetin Alfa:
- Reblozyl (luspatercept):
- Rytelo (imetelstat):
How many LR-MDS patients requiring red blood cell transfusions do you expect to start the following in the next 3 months?
- Epoetin Alfa:
- Reblozyl (luspatercept):
- Rytelo (imetelstat):
How do you factor in the results of the RS- test when making treatment decisions for 2L RS- MDS patients? Please be specific
How do you expect fatigue as a side effect of the Reblozyl (luspatercept) treatment to impact your use of the treatment? Please be specific.
Under what circumstance, if any, are you using Rytelo (imetelstat) in the 2L setting? Please be specific.
How burdensome are the monitoring requirements for Rytelo (imetelstat)? Please be specific.
How would you rate Rytelo (imetelstat) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient willingness to try
- Payor access
How would you rate Reblozyl (luspatercept) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient willingness to try
- Payor access
How do you anticipate your use of Rytelo (imetelstat) to change over the next year? Select one.
- Increase in all lines:
- Increase only in later lines (3+):
- Stay the same:
- Use less:
Roughly what percentage (%) of patients on Rytelo (imetelstat) would you anticipate to discontinue use over a 1 year period due to unacceptable cytopenia?
Overall, does your use of Rytelo (imetelstat) reflect what is described in NCCN guidelines version 2.2025?
- Yes
- No
If not, can you describe key differences?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
